74 related articles for article (PubMed ID: 16365885)
1. Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity.
Yang HY; Yang H; Zhao R; Lee MH
J Cell Biochem; 2006 May; 98(1):128-38. PubMed ID: 16365885
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth.
Zhang Y; Yang HY; Zhang XC; Yang H; Tsai M; Lee MH
Oncogene; 2004 Sep; 23(42):7132-43. PubMed ID: 15273726
[TBL] [Abstract][Full Text] [Related]
3. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity.
Yang H; Zhao R; Yang HY; Lee MH
Oncogene; 2005 Mar; 24(11):1924-35. PubMed ID: 15688030
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of adenovirus-mediated p27kip1 lacking the Jab1-binding region enhances cytotoxicity and inhibits xenografted human cholangiocarcinoma growth.
Shiraso S; Katayose Y; Yamamoto K; Mizuma M; Yabuuchi S; Oda A; Rikiyama T; Onogawa T; Yoshida H; Hayashi H; Ohtsuka H; Motoi F; Egawa S; Kato J; Unno M
Anticancer Res; 2009 Jun; 29(6):2015-24. PubMed ID: 19528460
[TBL] [Abstract][Full Text] [Related]
5. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling.
Hulit J; Lee RJ; Li Z; Wang C; Katiyar S; Yang J; Quong AA; Wu K; Albanese C; Russell R; Di Vizio D; Koff A; Thummala S; Zhang H; Harrell J; Sun H; Muller WJ; Inghirami G; Lisanti MP; Pestell RG
Cancer Res; 2006 Sep; 66(17):8529-41. PubMed ID: 16951165
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1.
Jeon JH; Lee KN; Hwang CY; Kwon KS; You KH; Choi I
Cancer Res; 2005 Jun; 65(11):4485-9. PubMed ID: 15930262
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
Hsu MC; Chang HC; Hung WC
Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
[TBL] [Abstract][Full Text] [Related]
8. Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
Supriatno ; Harada K; Yoshida H; Sato M
Int J Oncol; 2005 Sep; 27(3):627-35. PubMed ID: 16077910
[TBL] [Abstract][Full Text] [Related]
9. p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis.
Yang HY; Shao R; Hung MC; Lee MH
Oncogene; 2001 Jun; 20(28):3695-702. PubMed ID: 11439332
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1.
Hsieh YH; Su IJ; Wang HC; Tsai JH; Huang YJ; Chang WW; Lai MD; Lei HY; Huang W
Mol Cancer Res; 2007 Oct; 5(10):1063-72. PubMed ID: 17951406
[TBL] [Abstract][Full Text] [Related]
11. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance.
Li L; Iwamoto Y; Berezovskaya A; Boussiotis VA
Nat Immunol; 2006 Nov; 7(11):1157-65. PubMed ID: 17013388
[TBL] [Abstract][Full Text] [Related]
12. Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma.
Berg JP; Zhou Q; Breuhahn K; Schirmacher P; Patil MA; Chen X; Schäfer N; Höller TT; Fischer HP; Büttner R; Gütgemann I
Hum Pathol; 2007 Nov; 38(11):1621-7. PubMed ID: 17651785
[TBL] [Abstract][Full Text] [Related]
13. p27Kip1 localization depends on the tumor suppressor protein tuberin.
Rosner M; Freilinger A; Hanneder M; Fujita N; Lubec G; Tsuruo T; Hengstschläger M
Hum Mol Genet; 2007 Jul; 16(13):1541-56. PubMed ID: 17470459
[TBL] [Abstract][Full Text] [Related]
14. Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer's dementia patients.
Muñoz U; Bartolomé F; Bermejo F; Martín-Requero A
Neurobiol Aging; 2008 Oct; 29(10):1474-84. PubMed ID: 17448572
[TBL] [Abstract][Full Text] [Related]
15. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
16. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
17. Post-translational regulation of the tumor suppressor p27(KIP1).
Vervoorts J; Lüscher B
Cell Mol Life Sci; 2008 Oct; 65(20):3255-64. PubMed ID: 18636226
[TBL] [Abstract][Full Text] [Related]
18. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase.
Baasner S; von Melchner H; Klenner T; Hilgard P; Beckers T
Oncogene; 1996 Sep; 13(5):901-11. PubMed ID: 8806679
[TBL] [Abstract][Full Text] [Related]
19. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
20. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity.
Wu FY; Wang SE; Sanders ME; Shin I; Rojo F; Baselga J; Arteaga CL
Cancer Res; 2006 Feb; 66(4):2162-72. PubMed ID: 16489017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
